Fyarro(sirolimus) albumin (Fyarro) is a drug developed by Edison Pharmaceuticals (AADI) in the United States. The following mainly explains the diseases that may be caused by the use of Fyarro(sirolimus) albumin.

Diseases that may be caused by the use of Fyarro(sirolimus) albumin

All drugs have certain drug toxicity, so the use of Fyarro(sirolimus) albumin (Fyarro) may cause damage to the patient's body and cause the following diseases:

1. Stomatitis

Patients treated with Fyarro(sirolimus) albumin may develop stomatitis, including oral ulcers and oral mucositis. It is recommended that patients suspend, reduce the dose, resume or permanently stop using Fyarro(sirolimus) albumin according to the severity of adverse reactions.

2. Bone marrow suppression

Fyarro(sirolimus) albumin (Fyarro) can cause bone marrow suppression, leading to symptoms such as anemia, thrombocytopenia and neutropenia in patients. Therefore, it is recommended to check blood cell counts every 2 months in the first year of treatment and every 3 months after treatment. If there are clinical indications, more frequent checks can be performed.

3. Infection

Fyarro(sirolimus) albumin may cause infection, including opportunistic infection.

4. Hypokalemia

Fyarro(sirolimus) albumin can cause hypokalemia. Patients should monitor potassium levels before starting to use it and supplement potassium according to the doctor's instructions.

5. Hyperglycemia

Fyarro(sirolimus) albumin can cause hyperglycemia. Therefore, patients should pay attention to monitoring fasting blood sugar before starting to use Fyarro(sirolimus) albumin. Non-diabetic patients should monitor blood sugar every 3 months during treatment, or monitor according to clinical needs. Diabetic patients need to monitor blood sugar more frequently.

6. Bleeding

Fyarro(sirolimus) albumin can cause severe bleeding, sometimes even fatal bleeding.

7. Allergic reaction

Patients may experience hypersensitivity reactions after using Fyarro(sirolimus) albumin, including allergic angioedema, exfoliative dermatitis and allergic vasculitis. Therefore, during and after the infusion of Fyarro(sirolimus) albumin, closely monitor the patient's infusion reaction, monitor the patient for at least 2 hours after the first infusion, and monitor each subsequent infusion according to clinical needs.

In addition to the above, the use of Fyarro(sirolimus) albumin may also cause interstitial lung disease (ILD)/non-infectious pneumonia, male infertility, and other adverse reactions such as fatigue, rash, nausea, edema, diarrhea, musculoskeletal pain, weight loss, decreased appetite, cough, vomiting and dysphagia.

If patients experience discomfort after using Fyarro(sirolimus) albumin, it is recommended to wait for relief. If it continues to be unrelieved or worsens, they should go to the hospital for treatment in time to avoid blindly increasing or decreasing the dosage or stopping the medication to prevent affecting the degree of disease treatment or affecting their own health.